For Patients and Families
For Healthcare Professionals

Are you a healthcare professional?

I am

Go back

Knopp Biosciences
  • Asthma
    • What is Eosinophilic Asthma?
    • Dexpramipexole
  • Kv7 in Epilepsy
  • Knopp Biosciences
  • News & Resources
  • For Healthcare Professionals
social-link social-link social-link
Stay In Touch With KNOPP

News and Resources

Choose an area of interest:

Eosinophilic Asthma Epileptic Encephalopathy Company News
  • All
03.20.19

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma

Discover this News
09.08.18

Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases

Discover this News
05.10.18

Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood

Discover this News
01.01.18

American Society of Hematology: “Dexpramipexole as an oral steriod-sparing agent in hypereosinophilic syndromes”

Discover this News
09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Discover this News
1 2
social-link social-link social-link
Knopp Biosciences
  • Asthma
    • What is Eosinophilic Asthma?
    • Dexpramipexole
  • Kv7 in Epilepsy
  • Knopp Biosciences
  • News & Resources
Stay In Touch With KNOPP +1 412-488-1776
© Copyright 2022 Knopp Biosciences LLC. All Rights Reserved
Privacy Policy Terms of Use FCOI Policy
social-link social-link social-link

Knopp Disclaimer

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.